Autoimmune diseases are a type of condition in which the body’s immune system begins to attack and terminate healthy cells and tissues within the body. In autoimmune disease patients, the body is unable to differentiate between healthy cells and attacking viral or bacterial agents. This results in white bloods cells indiscriminately destroying any other types of cells. The underlying cause of autoimmune diseases is not fully known.  Autoimmune blistering diseases are a group of disorders in which the body mistakenly attacks healthy tissue, causing blistering lesions that primarily affect the skin and mucous and membranes.

Psoriasis is a common and chronic incurable but treatable skin disorder. Psoriasis is a multi-organ disease, and the autoimmune process in the skin affects other organs such as the joints (psoriatic arthritis), blood vessel endothelium (atherosclerosis and cardiovascular comorbidities), fat tissue, liver (non-alcoholic fatty liver disease), and probably the central nervous system (depression). This study addressed a very relevant question of whether psoriasis affects the course of pregnancy.

According to the International Federation of Psoriasis Associations (IFPA), about three per cent of the world’s population has some form of psoriasis. In the United States, there are about 150,000 new cases every year, affecting about two per cent of the population, according to the Cleveland Clinic.

Psoriasis is an uncomfortable, unsightly skin condition. However, for those with psoriasis, it means an often painful and intensely itchy chronic autoimmune disease that appears on the skin. According to the National Psoriasis Foundation, psoriasis is the most common autoimmune disorder in the United States, affecting up to 7.5 million people.

Psoriasis is a chronic immune-mediated disease estimated to affect more than 125 million people worldwide. It affects 3 percent to 4 percent of the U.S. population, and the psychological impact of psoriasis can be substantial.

The exact cause of psoriasis is unknown. However, it's believed that your immune system and genes may contribute to the condition. T-cells normally fight viruses and bacteria. In psoriasis, they may start to attack healthy skin cells.  Our Body increases its production of new skin cells in response to this attack. These new skin cells move to the outer layer of your skin before dead skin cells shed, triggering scaly skin patches.

 Many patients with psoriasis in the United States do not receive sufficient treatment to control the disease is suggested by an analysis of surveys performed by the National Psoriasis Foundation between 2003 and 2011. Among the 5604 survey respondents with psoriasis, 52 percent expressed dissatisfaction with their treatment. Many patients received no treatment, including 37 to 49 percent of respondents with mild psoriasis, 24 to 36 percent of respondents with moderate psoriasis, and 9 to 30 percent of respondents with severe psoriasis.

Psoriasis is a life-long condition that can be controlled with treatment. It may go away for a long time and then return. With proper treatment it does not affect your overall health. Some people with psoriasis have a type of arthritis.

Psoriatic arthritis can develop slowly with mild symptoms, or it can develop quickly and be severe. Early recognition, diagnosis and treatment of psoriatic arthritis can help prevent or limit extensive joint damage that occurs in later stages of the disease. A dermatologist is a doctor who specializes in skin diseases. There’s no cure for psoriasis. But with treatment, you can reduce inflammation and skin irritation.

TechNavio's analysts forecast the Global Psoriasis Therapeutics market to grow at a CAGR of 9.95 percent over the period 2014-2019. In 2014, the value of the psoriasis therapeutics market in APAC amounted to an estimated $435m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $773m. The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination.

Psoriatic arthritis causes inflammation in your joints. It happens because our  immune system is overactive. It affects mostly people who have psoriasis, a skin disease that's also related to the immune system. Sometimes doctors misdiagnose it as gout, rheumatoid arthritis, or osteoarthritis.

Medication can control the inflammation, ease your symptoms, and prevent long-term joint damage. Exercise is another important way to take charge of the symptoms, including joint problems and fatigue. Approximately 10% to 20% of those with psoriasis may develop some form of arthritis. 80% the arthritis develops after the appearance of psoriasis. Some people may develop a condition (uveitis) of the eye which may cause redness and inflammation (if you are concerned about this seek medical advice).

Management of psoriasis may involve topical and systemic medication, phototherapy, stress reduction, climatotherapy, and various adjuncts such as sunshine, moisturizers, salicylic acid, and other keratolytics such as urea. 

Psoriasis can increase your risk for other illnesses. Some people develop psoriatic arthritis, which can cause severe joint damage. Psoriasis can develop anywhere on the body and become a widespread problem, The Problem may  arise of  low self-esteem, social isolation, and depression.

Phototherapy or light therapy, involves exposing the skin to ultraviolet light on a regular basis and under medical supervision. Treatments are done in a doctor's office or psoriasis clinic or at home with phototherapy unit. The key to success with light therapy is consistency.
For treating skin disease, Narrowband ultraviolet B (UVB) light is the most common type of phototherapy. This uses a special machine to emit UVB light at 311-312 nm, which is the most beneficial portion of natural sunlight for skin diseases. Importantly, it also avoids the UVA aspect of sunlight which is very damaging to skin, and can accelerate aging and progression towards skin cancers.

Psoriasis is incurable, it responds well to many topical and systemic treatments. Cyclosporine may be used for severe, difficult-to-treat cases of widespread psoriasis. Improvement and results may be very rapid in onset. Major possible side effects include kidney and blood-pressure problems. Methotrexate is a common drug used for rheumatoid arthritis, and it has been used effectively for many years in psoriasis. The drug may cause liver and lung damage. Close physician monitoring and monthly to quarterly visits and labs are generally required.

Skin disorders are common in children. Children can experience many of the same skin conditions as adults. Infants and toddlers are also at risk for diaper-related skin problems. Since children have more frequent exposure to other children and germs, they may also develop skin disorders that rarely occur in adults. Psoriasis is a chronic life-altering skin disorder with possible systemic comorbidities. Psoriasis is a chronic skin condition that occurs in children and adults. The typical appearance is of red, thickened, scaly patches on the skin (plaques). These plaques can vary in size and distribution from person to person. In some people it may affect small areas of skin while others may have large areas covering their body.

Scientists will use the samples for research that hopes to uncover the unknowns about the genetics of psoriatic disease and its causes. Scientists have uncovered links between certain genes and psoriasis susceptibility, there is still much to discover about psoriatic disease and its causes. According to medical researchers they have identified approximately half of the genes that predispose individuals to developing psoriasis. New psoriasis biomarkers, which will allow doctors in the future to determine how an individual’s psoriasis will behave and which medications will work best.

With the worldwide prevalence of psoriasis estimated at nearly 14 million people in 2004, there is increasing demand for therapeutics that control disease symptoms with greater efficacy and longer time duration, treat the disease on a much more comprehensive level, and improve the quality of life for patients.

The worldwide psoriasis therapeutics market is estimated to reach $1.085B in 2004 and will continue to grow at a compound annual rate of 23.6% to reach approximately $3.12B worldwide by 2009. Growth will be driven by the introduction of several biologic immunosuppressives along with Amgen's currently available Enbrel, Biogen Idec's Amevive, and Genentech and XOMA's Raptiva.

Innovation and support for entrepreneurship are key drivers for the development of economies. Entrepreneur Investment meet is helpful to companies to raise funds with trusted and smart investors in National and international markets.  The objective of the meet is to get the investors and willing to go through due diligence process to understand if they want to invest. In addition to capital, entrepreneurs need a favourable environment to launch and develop their dynamic businesses. This environment, commonly called an "entrepreneurial ecosystem".

Epidemiologists forecast that the one-year total prevalent cases of atopic dermatitis in the 9MM will increase from 66,289,178 cases in 2014 to 67,630,097 cases in 2024 with an annual growth rate (AGR) of 0.20% and the prevalent cases of atopic dermatitis in the 9MM from 2014-2024 using country-specific studies that provided one-year total prevalence of atopic dermatitis in these markets obtained through symptom-based surveys